新学術領域研究（研究領域提案型） 脳タンパク質老化と認知症制御

国際活動支援班はこちら

ENGLISH

ホーム > 業績 > 国際学会

国際学会

⬛︎2017

  1. Sobue G.Perspectives on therapeutic research
    for ALS.3rd World Centenarians Initiative International Symposium on Amyotrophic Lateral Sclerosis –giving new hope: novel therapies toward a cure-. Osaka, February 19, 2016
  2. Sobue G.Perspectives on therapeutic research for ALS –General review of therapeutics, and edaravone treatment-. 大韓神経筋肉疾患学会 , Seoul, Korea, March 25, 2016
  3. Okamura N. AONeuro Symposium – Neurotrauma, February 28, 2016, Sendai
  4. Okamura N. Mind Brain Conference “From Molecules to the Universe: Advancing Biomedical Sciences and Engineering”, February 24, 2016, Hamamatsu
  5. Makoto Higuchi, Hitoshi Shimada, Naruhiko Sahara, Tetsuya Suhara Conformational heterogeneity of tau lesions captured by PET and its clinical significance 14th International Athens/ Springfield Symposium on Advances in Alzheimer Therapy, 14th International Athens/Springfield Symposium, 2016-03-11
  6. Makoto Higuchi.Protein imaging focusing on tau and alpha-synuclein The 15th International Parkinson’s Disease Symposium in Takamatsu, International Parkinson’s Disease Symposium in Takamatsu, 2016-02-06
  7. Matsumoto, G., Nukina, N., Mori, N., p62- mediated selective autophagy in aged neurons, The 6th Busan-Nagasaki Joint Seminar on Aging Research, March 11, 2016, Seacloud Hotel in Busan, South Korea
  8. Takashima A. Mechanism of Neurodegeneration through Tau and Therapy for AD.(symposium) The 1st International Gachon Neuroscience Symposium, 24 Feb. 2016, Incheon, Korea.
  9. Furukawa Y. Protein conformational disorder leading to neurodegenerative diseases. The 3rd Mini-Symposium on Cutting-Edge Chemistry, Hsinchu, Taiwan, March 11, 2016
  10. Hideyuki Okano : Challenge toward Spinal Cord Injury and using iPS cell Technologies UK-JAPAN Life Innovation Symposium. : UK-JAPAN Life Innovation Symposium, 2016.2.22 *2016.2.22-23 (Tokyo Branch Kyoto University & LiSE KING SKYFRONT Sinagawa & Kawasaki, Japan)
  11. Hideyuki Okano : Challenge toward Spinal Cord Injury using iPS cell Technologies.: CiRA/ ISSCR 2016 International Symposia, 2016.3.24 *2016.3.22-24 (Kyoto University Clock Tower Centennial Hall, Kyoto, Japan)
  12. Hirohisa Watanabe, Masahisa Katsuno, Gen Sobue Takamatsu14th International Parkinson’ s disease symposium in Takamatsu Lewy body disease: hot topics, autonomic failure, What’s new?2015.02.28
  13. Hideyuki Okano : Modeling Psychiatric/ Neurological disorders using iPS cell technologies and transgenic non-human primates.2015.04.12. (International Symposium on Cell Physiology and Aging Research Kaohsiung Medical University (KMU), Kaohsiung, Taiwan)
  14. Hideyuki Okano : Modeling Human Psychiatric/ Neurological Disorders using Transgenic technologies and Genome-Editing in Non-human Primates.2015.04.21. (24 th annual Colloque Médecine et Recherche in the Neurosciences series, #Cloud, Paris, FranceGenome Editing in Neurosciences)
  15. Hideyuki Okano : Brain Mapping and Modeling Human Psychiatric/Neurological Disorders using Transgenic technologies and Genome-Editing inNon-humanPrimates.2015.05.02(. Scientific meeting on animal models of neurodegenerative Disorders, Paris, France)
  16. Hideyuki Okano : Using Genetics to Deconstruct Neural Circuits session Alpbach Congress Centrum in Alpbach, 2015.05.23-27(2016 Keystone Symposia on The Brain, Austria)
  17. Hideyuki Okano : Brain Science and Modeling 72 Neurological Diseases using Transgenic and Genome Editing Technologies. : Dr. Austin Smith Lab Seminar, 2015.4.22 *2015.4.22 (Stem Cell Institute, University of Cambridge, Cambridge, UK)
  18. Hideyuki Okano : Disease Modeling and Brain Mapping using transgenic marmosets. : Janelia Marmoset Workshop ”The common marmoset as a transgenic model of the human brain in health and disease”, 2015.6.16 *2015.6.14-16 (Janelia Research Campus, Howard Hughes Medical Institute, Virginia, USA)
  19. Hideyuki Okano : Brain Mapping Project in Japan:Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/ MINDS). : Cold Spring Harbor Asia (CSHA) Conference on International Brain Project, 2015.6.19 *2015.6.19-22 (Suzhou Industrial Park Conference Center, Suzhou, People’s Republic of China, PRC)
  20. Hideyuki Okano : Modeling neurological and psychiatric disorders using iPSCs technologies and transgenic non-human primates. : The ISSCR Annual Meeting, 2015.6.25 *2015.6.24-27 (Stockholmsmassan Exhibition and Convention Center, Stockholm, Sweden)
  21. Hideyuki Okano : Neuronal damage and regenerative medicine. : Center for Animal Disease Model International Symposium (CADMIS) 2015̶Frontiers of Immunology and Neurobiology̶( 東京理科大学ヒト疾患モデ ル研究センター国際シンポジウム ), 2015.7.21 *2015.7.21 (Gakushikaikan,Tokyo)
  22. Hideyuki Okano : Modeling Human Neurological/Psychiatric Disorders using iPS cells and Transgenic Non-Human Primates. : Breakthroughs in Molecular Genetics in Model Organisms Symposium, 2015.8.22 *2015.8.22 (UC Santa Barbara, Santa Barbara, CA, USA)
  23. Hideyuki Okano : Modeling Human Neurological Diseases using iPS cells and Transgenic Non- Human Primates : CHA Bio Complex Seminar, 2015.8.27 *2015.8.27 (CHA Bio Complex, Seoul, Korea)
  24. Hideyuki Okano : Regenerative Medicine and Disease Modeling with iPS cells technologies. :1th Annual Meeting of Korean Society for Stem Cell Research”Presidential Session -Today’s Stem Cell Research in Asia, 2015.8.28, *2015.8.27- 28 (Grand Hilton Seoul Hotel, Seoul, Korea)
  25. Hideyuki Okano : Preemptive Medicine for Dementia: Solutions for a ‘super-aging’ society. : International Conference on Cognitive Decline and Its Economic Consequences 国際会議「認知 症社会における経済的挑戦と機会」, 2015.10.5 *2015.10.5-6 (North uilding Hall on Mita Campus, Keio University, Tokyo, Japan)
  26. Hideyuki Okano: Modeling Neurological Diseases using iPS cells and Transgenic Non-human Primates. : The first International Symposium
    of Brain Protein Aging and Dementia Control, 2015.10.10 *2015.10.9-10 (Noyori Conference Hall (NCH), Nagoya, Japan)
  27. Hideyuki Okano : Modeling psychiatric/ neurological disorders using ips cell technologies and transgenic non-human primates. : Cell Symposia:Human Genomics, 2015.11.9 *2015.11.9 *2015.11.8-10 (the Matrix building, 30 Biopolis Street, Singapore)
  28. Hideyuki Okano : Modeling Psychiatric/ Neurological disorders using iPS cell technologies and transgenic non-human primates.: 29th Annual Conference of he International Mammalian Genome Society, Keynote Lecture, 2015.11.11 *2015.11.8-11 (Yokohama Port Opening Memorial Hall, Yokohama, Japan)
  29. Hideyuki Okano : Preemptive Approaches for Neurodegenerative Disease and Dementia : 2015 WAFSF “Regenerative Medicine: Let’s Talk Business!” , 2015.11.12 *2015.11.12-13 (Golden Gate Club, San Francisco, USA)
  30. Hideyuki Okano : Transgenic and Genome Editing Technologies in Non-Human Primates. : TGE2015 Conference on Transposition and Genome Engineering 2015, Invited Lecture, 2015.11.19 *2015.11.17-20 (Nara Kasugano International Forum IRAKA, Nara, Japan)
  31. Hideyuki Okano : Modeling Psychiatric/ Neurological disorders using iPS cell technologies and transgenic non-human primates. : THE 12TH NIKKO INTERNATIONAL SYMPOSIUM
    2015 FRONTIERS IN TRANSLATIONAL NEUROSCIENCE, 2015.11.20 *2015.11.20(JMU Education & Research Center, Shimotsuke, Japan)
  32. Hideyuki Okano: Modeling Human Neurological/ Psychiatric Diseases using iPS cells and Transgenic Non-Human Primates. : Regenerative Medicine Seminar Series@Stanford, 2015.12.10 *2015.12.10 (Stanford University, Stanford, CA, USA)
  33. Takashima A. Mechanism of Neurodegeneration through Tau and Therapy for AD.(Keynote speaker) The 7th International High Level Forum on Exercise and Health – International Conference of Exercise Intervention on Alzheimer’s disease (ICEIAD), 7-8 May 2016, Shanghai, China
  34. Takashima A Aging and Tau (symposium)Asian Aging Core for Longevity (AACL) 10 years and Beyond Japan-Korea Joint Seminars, Osaka, Japan. March 12, 2015.
  35. Hisanaga S, Kimura T. Reevaluation of physiological and pathological phosphorylation of tau in vitro to human brains 25th International Society for Neurochemistry, Cairns, Australia, Aug. 23-25. 2015
  36. Okamura N. Busan Paik Hospital Neurodegenerative Disease Symposium, November 27, 2015, Busan
  37. Okamura N. 2015 IPA 17th International Congress , October 15, 2015, Berlin
  38. Okamura N. Tohoku Forum for Creativity: Frontier of Brain Science Satellite Symposium “Neuroimaging and its impact on our lives”, July 28, 2015, Kobe
  39. Okamura N. SNMMI 2015 Annual Meeting, June 6, 2015, Baltimore
  40. Okamura N. ADPD Imaging Symposium 2015, March 17, 2015, Nice
  41. Hisanaga, S. Neuronal protein kinase LMTK1 regulates neurite outgrowth through Rab11- dependent endosomal trafficking in a Cdk5- dependent manner EMBO Workshop, PUERTO MONTT, Chile, Mar 23-26, 2015
  42. Hisanaga, S., Kimura, T.Reevaluation of physiological and pathological phosphorylation of tau in vitro to human brains 25th ISN meeting, Cairns, Australia, Aug. 23-25. 2015.
  43. Hasegawa M, Molecular analyses of pathological tau in tauopathy brains. Brain Protein Aging and Dementia Control. 1st International Symposium. Molecular bases of brain protein aging. 2015. 10.9, Nagoya
  44. Osamu Onodera How does the cerebral small vessel system contribute the brain function in aging?–Lesson from the hereditary small vessel disease–Brain Protein Aging and Dementia Control 1st International Symposium 2015/10/9 Nagoya
  45. Yamagichi.Y RIKEN-Max Planck Joint Research Center for Systems Chemical Biology 4th Annual Symposium, Kobe, Japan 2015. 5.11-14
  46. Yamaguchi.Y RIKEN-ACADEMIA Sinica Joint Conference on Chemical Biology, Taipei, Taiwan 2015. 10. 14-17
  47. Makoto Higuchi. Symposium in Nobel Forum: In vivo molecular imaging of alpha-synuclein, Karolinska Institutet, 2015-12-18
  48. Makoto Higuchi. Tracking tau pathogenesis in living brains The 9th International Congress of the Asian Society Against Dementia, Asian Society Against Dementia (ASAD), 2015-09-15
  49. OnoM.「MolecularImagingof・-Amyloid Plaques in Alzheimer’s Disease: From Molecular Design to Clinical Research」1st Kyoto University-UC San Diego Joint Symposium, New Era of Trans-Pacific Knowledge Interactions. 2015. 3. 12. ,Kyoto
  50. Murakami T. Alteration of corticobulbar excitability during speech perception. International TMS Symposium 2015/6/7, Fukushima.
  51. Ubiquitination of Dynamin 2 and Snx18 by Mib1 promotes Dll1 endocytosis and Notch signaling. Makoto Okano, Hiromi Matsuo, Yuya Nishimura, Katsuto Hozumi, Saho Yoshioka, Ayako Tonoki, Motoyuki Itoh Notch meeting, Athens, October 7, 2015.
  52. Furukawa Y. Lights and shadows of Cu,Zn- superoxide dismutase. The 17th International Conference on Biological Inorganic Chemistry, Beijing, China, July 20-24, 2015
  53. Masaki Fukata Regulatory mechanism for local palmitoylation cycles on PSD-95. FASEB Science Research Conference “Protein Lipidation, Signaling, and Membrane Domains”. (Saxtons River, VT, USA) (2015.7.22)
  54. Masaki Fukata. Postsynaptic nanodomain regulated by PSD-95 palmitoylation machinery. Pacifichem 2015, (2015.12.15) (Honolulu, HI, USA)
  55. Shigeomi Shimizu“Biological Roles of Autophagic Cell Death”Japan Australia Meeting on Cell Death (Oct 21-23, 2015, Melbourne)
  56. Mochizuki H. Parkinson’s disease and α-synuclein. Australian National University (ANU) & IPR Joint Symposium 2015 “PROTEIN STRUCTURE AND FUNCTION”. Nov.16, 2015. Australia.

⬛︎2016

  1. Okamura N. Novel tracer development and potential application for movement disorders. 3rd Taiwan International Congress of Parkinson’s Disease and Movement Disorders, March 19, 2017, Taipei
  2. Harada R, Ishiki A, Furumoto S, Furukawa K, Tashiro M, Arai H, Yanai K, Kudo Y, Okamura N. Characterizing the “off-target” binding of 18F-THK5351 in Alzheimer’s disease: correlation between ante-mortem and postmortem findings
  3. Okamura N, Harada R, Ishiki A, Furukawa K, Kikuchi A, Hasegawa T, Aoki M, Furumoto S, Tashiro M, Yanai K, Arai H, Kudo Y. Longitudinal analysis of [18F]THK5351 tau PET images in patients with Alzheimer’s disease and corticobasal syndrome. CTAD 2016, December 10, 2016, San Diego
  4. Okamura N. Development of THK tau tracers. Tau PET Futures Meeting, October 13, 2016, San Francisco
  5. Okamura N, Ishiki A, Furukawa K, Harada R, Tomita N, Furumoto S, Tashiro M, Yanai K, Arai H, Kudo Y. [F-18] THK5351 retention is associated with the progression of brain atrophy in patients with Alzheimer’s disease. AAIC 2016, July 22-28, 2016, Toronto
  6. Okamura N. Recent clinical studies with THK tau tracers. SNMMI 2016 Annual Meeting, June 13, 2016, San Diego
  7. The 1st International Gachon Neuroscience Symposium, Neurosciense Research Institute, Gachon University, February 24, 2016 @ Gachon/Korea
  8. International Conference of Exercise Intervention on Alzheimer’s Disease (ICEIAD)　May 6, 2016 @Shanghai/China
  9. Alzheimer’s Association International Conference(AAIC), July 24 – 28 @ Toronto/ Canada
  10. AD International Conference in Hefei, October 15, 2016 Hefei/China
  11. Society for Neuroscience(SFN) 2016,　November 12-16, 2016 @ Sandiego/USA
  12. アジア太平洋神経化学会,　August 26-30 @Kuala Lumpur/Malaysia
  13. Society for Neuroscience(SFN) 2016,　November 12-16, 2016 @ Sandiego/USA
  14. Accumulation of phosphorylated tau in neurons in FUS-silenced mice. Society for Neuroscience(SFN) 2016　November 12-16, 2016 @ Sandiego/USA
  15. Loss of SFPQ, an intra-nuclear counterpart of FUS causes FTLD-like phenotypes. Society for Neuroscience(SFN) 2016, November 12-16, 2016 @ Sandiego/USA
  16. Loss of SFPQ, an intra-nuclear counterpart of FUS causes FTLD-like phenotypes.Society for Neuroscience(SFN) 2016　November 12-16, 2016 @ Sandiego/USA
  17. Development of a Molecular Analysis Chip for Sigle Cells on 2D-Plane with Positional Information International Conference on Single Cell Research 2016 　November 16-17 @ Tokyo/Japan
  18. Imaging Mass Spectrometry(IMS) for the Proteomic Studies of Experimental Autoimmune Encephalomyelitis(EAE) Mouse HUPO(Human Proteome Organization) 2016 September 18-22, 2016 @Taipei
  19. Hasegawa M: Tau / TDP-43 prions, Invited Lectures: Expansion of prion concept, PRION 2016, Tokyo [2016, 5. 10.]
  20.  Hasegawa M: αSynuclein prions, Luncheon Seminar 4, PRION 2016, Tokyo [2016. 5. 13.]
  21. Hasegawa M: Molecular Mechanisms of Neurodegenerative Tauopathies. 14th Igakuken International Symposium Tokyo [2016. 6. 30.]
  22. Hasegawa M: Molecular mechanisms of TDP-43 aggregation. Brain Protein Aging and Dementia Control International Workshop. Nagoya [2016.9.9.]
  23. Tarutani A, Suzuki G, Shimozawa A, Nonaka T, Hisanaga S, Hasegawa M: Prion-like properties of fragmented α-synuclein fibrils. 10th International Conference on Frontotemporal Dementias. (Munich, Germany) [2016.9.2.]
  24. Hosokawa M, Arai T, Kondo H, Serrano GE, Beach TG, Hasegawa M, Akiyama H. Multiple accumulation of neurodegenerative disease-related proteins in familial granulin mutation brains. 30th CINP World Congress of Neuropsychopharmacology (Seoul, Republic of Korea) [2016. 7. 5]
  25.  Hosokawa M, Arai T, Kondo H, Serrano GE, Beach TG, Hasegawa M, Akiyama H. Phosphorylated tau and α-synuclein accumulation in familial granulin mutation cases. Alzheimer’s Association International Conference 2016 (Toronto, Canada) [2016. 7. 26]
  26.  Hosokawa M, Arai T, Kondo H, Serrano GE, Beach TG, Hasegawa M, Akiyama H. Multiple accumulation of neurodegenerative disease-related proteins in familial granulin mutation brains. 10th International Conference on Frontotemporal Dementias (Munich, Germany) [2016. 9. 1]
  27. Kawakami I, Arai T, Kobayashi Z, Yokota O, Nonaka T, Niizato K, Oshima K, Higashi S, Hosokawa M, Hasegawa M, Akiyama H. Clinical and pathological study of FTLD-FUS presenting chorea. 10th International Conference on Frontotemporal Dementias (Munich, Germany) [2016. 9. 1]
  28.  Overexpression of intrinsic TDP-43 by disruption of the autoregulation in vivo. Akihiro Sugai, Taisuke Kato, Masatoyo Nishizawa, Osamu Onodera EMBO | EMBL Symposia Mechanisms of Neurodegeneration 2015.6.14-17
  29.  Analysis of intracellular distribution of TDP-43 mRNA in affected spinal motor neuron with ALS. Taisuke Kato, Akihide Koyama, Akihiro Sugai, Yasuko Toyoshima, Akiyoshi Kakita, Hitoshi Takahashi, Masatoyo Nishizawa, Osamu Onodera. Key stone symposium. Common Mechanisms of Neurodegeneration 2016.6.12-16
  30. The expression of Human endogenous retrovirus-K in the neuronal tissues of Japanese ALS patients. Tomohiko Ishihara, Akihide Koyama, Taisuke Kato, Ryoko Takeuchi, Mari Tada, Akiyoshi Kakita, Osamu Onodera. Key stone symposium. Common Mechanisms of Neurodegeneration, 2016.6.12-16
  31. Vicious cycle of TDP-43 up-regulation in spinal motor neurons with ALS. Osamu Onodera. Brain Protein Aging and Dementia . International Workshop 2016 2016.9．9
  32.  International stroke conference 2017 Huston. Feb. 22, 2017. M2 Microglia Preconditioned by Oxygen Glucose Deprivation Promotes Functional Recovery in Ischemic Rats Masato Kanazawa, Minami Miura, Masafumi Toriyabe, Misaki Koyama, Masahiro Hatakeyama, Masanori Ishikawa, Brain Res Inst, Niigata Univ, Niigata, Japan; Takashi Nakajima, Niigata Natl Hosp, Natl Hosp Organization, Niigata, Japan; Osamu Onodera, Tetsuya Takahashi, Masatoyo Nishizawa, Takayoshi Shimohata, Brain Res Inst, Niigata Univ, Niigata, Japan
  33. International stroke conference 2017 Huston. Feb. 23, 2017. Characteristic Brain MRI Features of Manifesting Heterozygotes With Cerebral Autosomal Recessive Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. Masahiro Uemura, Brain Res Inst (BRI), Niigata Univ, Niigata, Japan; Hiroaki Nozaki, Niigata Univ, Niigata, Japan; Yumi Sekine, Brain Res Inst (BRI), Niigata Univ, Niigata, Japan; Ikuko Mizuta, Kyoto Prefectural Univ of Med, Kyoto, Japan; Tomoko Noda, Ichinomiya Municipal Hosp, Aichi, Japan; Kazuhide Miyazaki, Shiseikai-Daini Hosp, Tokyo, Japan; Muichi Kaito, Kanazawa Medical Univ, Kanazawa, Japan; Yoshinori Nishimoto, Keio Univ Sch of Med, Tokyo, Japan; Yutaka Shimoe, Kashima Rosai Hosp, Ibaraki, Japan; Akiko Shirata, Kiyomi Yamane, Ohta Atami Hosp, Fukushima, Japan; Sohei Yanagawa, Iida Municipal Hosp, Nagano, Japan; Mikio Hirayama, Kasugai Municipal Hosp, Aichi, Japan; Masato Tamura, Nagaoka-Nishi Hosp, Niigata, Japan; Toshiki Mizuno, Kyoto Prefectural Univ of Med, Kyoto, Japan; Masatoyo Nishizawa, Osamu Onodera, Brain Res Inst (BRI), Niigata Univ, Niigata, Japan
  34.  International stroke conference 2017 Huston. Feb. 23, 2017, Distinct Molecular Mechanisms of Htra1 Mutants in Manifesting Heterozygotes With Carasil. Hiroaki Nozaki, Taisuke Kato, Megumi Nihonmatsu, Yohei Saito, Niigata Univ, Niigata, Japan; Ikuko Mizuta, Kyoto Prefectural Univ of Med, Kyoto, Japan; Tomoko Noda, Ichinomiya Municipal Hosp, Aichi, Japan; Ryoko Koike, Nishi-Niigata Chuo Natl Hosp, Niigata, Japan; Kazuhide Miyazaki, Shiseikai-Daini Hosp, Tokyo, Japan; Muichi Kaito, Kanazawa Medical Univ, Ishikawa, Japan; Shoichi Ito, Chiba Univ, Chiba, Japan; Masahiro Makino, Nantan General Hosp, Kyoto, Japan; Akihide Koyama, Atsushi Shiga, Masahiro Uemura, YumiSekine, Niigata Univ, Niigata, Japan; Ayuka Murakami, Suzuko Moritani, Nagoya Medical Ctr, Aichi, Japan; Kenju Hara, Japanese Red Cross Akita Hosp, Akita, Japan; Akio Yokoseki, Ryozo Kuwano, Naoto Endo, Niigata Univ, Niigata, Japan; Takeshi Momotsu, Sado General Hosp, Niigata, Japan; Mari Yoshida, Aichi Medical Univ, Aichi, Japan; Masatoyo Nishizawa, Niigata Univ, Niigata, Japan; Toshiki Mizuno, Kyoto Prefectural Univ of Med, Kyoto, Japan; Osamu Onodera, Niigata Univ, Niigata, Japan
  35. 4th Symposium on RNA Metabolism in Neurological Disease. November 10-11, 2016 San Diego.A trade-off theory for TDP-43 proteinopathy; a ‘robust yet fragile’ nature of the autoregulation. Akihiro Sugai, Osamu Onodera
  36. 4th Symposium on RNA Metabolism in Neurological Disease. November 10-11, 2016 San Diego.Applying “CORRECT” for introducing a mutation in the MAPT gene. Yuka Koike, Akihide Koyama, Atsushi Shiga, Akio Yokoseki, Osamu Onodera
  37. Hideyuki Okano : Modeling Psychiatric/Neurological disorders using iPS cell technologies and transgenic non-human primates. : International Symposium on Cell Physiology and Aging Research, 2016.4.12 *2016.4.12 (Kaohsiung Medical University (KMU), Kaohsiung, Taiwan)
  38.  Hideyuki Okano : Modeling Human Psychiatric/Neurological Disorders using Transgenic technologies and Genome-Editing in Non-human Primates. : Genome Editing in Neurosciences (24 th annual Colloque Médecine et Recherche in the Neurosciences series), 2016.4.22 *2016.4.22 (#Cloud, Paris, France)
  39. Hideyuki Okano : Brain Mapping and Modeling Human Psychiatric/Neurological Disorders. : INSERM&AMED International Workshop ”Scientific meeting on animal models of neurodegenerative　disorders”, 2016.5.3　*2016.5.3 (Institut national de la santé et de la recherche médicale (INSERM), Paris, France)
  40. Hideyuki Okano : Disease Modeling and Brain Mapping Using Transgenic Marmosets. : Keystone Symposia Conference “State of the Brain(R1)”, 2016.5.26 *2016.5.22-26 (Alpbach Congress Centrum, Alpbach, Austria)
  41. Hideyuki Okano : Brain Mapping and Modeling Human Psychiatric/Neurological Disorders using Transgenic technologies and Genome-Editing in Non-human Primates. : The Brain Forum 2016, 2016.5.27 *2016.5.26-27 (SwissTech Convention Center, Ecublens, Swiss Confederation) Hideyuki Okano : Role of RNA-binding protein Musashi in Stem Cell Regulation and Cancer Development.: 18th Annual Meeting (21st Annual Meeting of the RNA Society)Luncheon Seminar, 2016.6.30 *2016.6.28-7.2 (Kyoto International Conference Center, Kyoto, Japan)
  42. Hideyuki Okano : Modelling human neurological diseases using iPS cells and transgenic non-human primates.:11th International Conference for Neurons and Brain Disease, 2016.7.16 *2016.7.14-16 (Sheraton Vancouver Wall Centre Hotel, Vancouver, Canada)
  43. Hideyuki Okano : Modeling Human Neurological/ Psychiatric Disorders using iPS Cells and Transgenic Non-human Primates.: Joint Symposium on Regenerative Medicine and Longevity, Washington University in St. Louis and Keio University, 2016.8.20 *2016.8.20 (Large Conference Room, llF, Building 2, Keio University Hospital,　Tokyo, Japan)
  44. Hideyuki Okano : Challenge toward clinical trial for spinal cord injury using iPS cells. : Cell Symposia – 10 Years of iPSCs, 2016.9.26 *2016.9.25-27 (CLAREMONT CLUB & SPA, A FAIRMONT HOTEL, Berkeley, California, United States)
  45. Hideyuki Okano : Stractual and Functional Mapping of Marmoset Brains and Desease Modeling using GM Marmoset.: Decode Summit 2016, 2016.9.28 *2016.9.28 (Four Seasons Hotel Silicon Valley, East Palo Alto, CA, USA)
  46. Hideyuki Okano : Modeling of Human Neurological/Psychiatric Disorders using IPS cells and Transgenic Non-Human Primates. : Special Gus Gurley Seminar, 2016.10.6 *2016.10.6 (Rathmann Auditorium, Neuroscience Research Institute • University of California, Santa Barbara, Santabarbara, California, USA)
  47. Hideyuki Okano : iPS Research in Fetal CNS Malformations. : the 44th Annual Meeting of the International Society for Pediatric Neurosurgery (ISPN), Plenary Session, 2016.10.26 *2016.10.24-27 (Kobe Portopia Hotel, Kobe, Japan)
  48.  Hideyuki Okano : MRI-based structural and functional　mapping of marmoset brains.: Neuroscience 2016, Nanosymposium, 2016.11.14 *2016.11.12-16 (San Diego Convention Center, San Diego, California, USA)
  49. Hideyuki Okano : New Insights from the Brain Mapping Project in Japan: Modeling Human Diseases with iPS cells and Transgenic Non-Human Primates.: UC San Diego Medical Education & Telemedicine Building Learning Center Seminar, 2016.11.16*2016.11.16 (UC San Diego Medical Education & Telemedicine Building Learning Center,　San Diego, California, USA)
  50. Hideyuki Okano : Challenge toward Clinical trial for Spinal Cord Injury using iPS cells.: Stanford Burnham Prebys Medical Discovery Institute Seminar, 2016.11.16*2016.11.16 (Stanford Burnham Prebys Medical Discovery Institute, Stanford, California, USA)
  51. Hideyuki Okano : Structural and functional mapping of marmoset brain.: NSF-AMED Workshop, Comparative Principles of Brain Architecture and Functions, 2016.11.18*2016.11.17-18 (Marriott Marquis San Diego Marina, San Diego, California, USA)
  52. Hideyuki Okano : Brain/MINDS: Brain Mapping Projects in Japan.: 3rd Annual Brain InitiativeR Investigators Meeting,2016.12.12 *2016.12.12-14 (Bethesda North Marriott Hotel & Conference Center, Bethesda, Maryland, USA)
  53. In vivo multimodal imaging of tauopathy revealed a rapid turnover of pathological tau inclusions in a tauopathy mouse model
    Naruhiko Sahara, Hiroyuki Takuwa, Ai Ishikawa, Takuya Urushihata, Takeharu Minamihisamatsu, Masaki Tokunaga, Masafumi Shimojo, Shoko Uchida, Izumi Matsumoto, Ming-Rong Zhang, Tetsuya Suhara, Makoto Higuchi SFN2016北米神経科学会, Society for Neuroscience, 2016-11-16
  54. In vivo assessment of synaptic properties in rTg4510 tauopathy transgenic mouse model by positron emission tomography Masafumi Shimojo, Masaki Tokunaga, Hiroyuki
    Takuwa, Yuhei Takado, Takeharu Minamihisamatsu, Ming-Rong Zhang, Tetsuya Suhara, Makoto Higuchi, Naruhiko Sahara SFN2016北米神経科学会, Society for Neuroscience, 2016-11-12
  55. Investigating the link between pathological tau accumulation, neuroinflammation and brain atrophy in a model of tauopathy Naruhiko Sahara, Ai ishikawa, Masaki Tokunaga, tokunaga, Takeharu Minamihisamatsu, minamihisamatsu, Maiko Ono, ono, Shoko Uchida,uchida, Izumi Matsumoto, matsumoto, Hiroyuki Takuwa, takuwa, Ming-Rong Zhang, Tetsuya Suhara,Makoto Higuchi Alzheimer’s association international conference,
    Alzheimer’s Association, 2016-07-24
  56. The Association Between Aβ and Tau Accumulation And Its Influence On Clinical Features In Aging And Alzheimer’s Disease Spectrum Brains: [11C]PBB3 PET Study
    Hitoshi Shimada, Tetsuya Suhara, Hitoshi Shinoto,Hironobu Endo, Fumitoshi Niwa, Soichiro Kitamura, Shigeki Hirano, Yasuyuki Kimura, Makiko Yamada, Naruhiko Sahara, Ming-Rong Zhang, Satoshi Kuwabara,Makoto Higuchi Alzheimer”s Association International
    Conference 2016, Alzheimer”s Association, 2016-07-23
  57. Kohei Sano, Yuko Kanada, Kengo Kanazaki, Ning Ding, Masahiro Ono, Hideo Saji. Brachytherapy using 90Y-labeled thermo-responsive polymers thatself-aggregate in tumor tissues Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting（San Diego）June 11-15, 2016
  58. Hiroyuki Watanabe, Masahiro Ono, Ayane Kitada, Hideo Saji. Novel Tau-SPECT Tracers Based on Benzoimidazopyridine for Imaging Tau Aggregates in Alzheimer’s Disease. Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting（San Diego）June 11-15, 2016
  59. The 15th Annual MCCS Symposium, Nov 10-11, 2016 (San Diego, USA)
  60. The 46th Annual Meeting of Society for Neuroscience, Nov 12-16, 2016 (San Diego, USA)
  61. NIPS International Symposium “Towards elucidation of memory engram”, Dec 5-7, 2016 (Okazaki, Japan)
  62. The 13th Japan-Korea Joint Symposium on Brain Science, and Cardiac and Smooth Muscles, Aug 26, 2016 (Saga, Japan)
  63. Hasegawa T., Oshima R., Tamai K., Takeda A, Tanaka N, Aoki M. ESCRT-0 dysfunction compromises autophagic degradation of protein aggregates and facilitates ER stress-mediated neurodegeneration via apoptotic and necroptotic pathways. （一般発表）, The 20th International Congress of Parkinson’s Disease and Movement Disorders･ベルリン（ドイツ）, 2016/06/21
  64. Gordon research conference, Girona, 2016
  65. 18th International Conference on Human Retrovirology: HTLV. (2017, Tokyo, Japan)
  66. The UK-Japan Spring Neuroscience Symposium, July 4-5, 2016
  67. Fujii T., Nishi E., Ito H., Yoshitomi H., Ohno M., Nishi K., Okabe N., Furu M., Morita Y., Azukizawa M., Okahata A. Collagen Antibody Induced Arthritis is Attenuated by the Gene Deletion of Nardilysin. ORS2016, March 5-8, 2016, Orlando, FL, USA
  68. Ohno M, Chen P-M, Hiwasa T, Nishi K, Saijo S, Sakamoto J, Morita Y, Watanabe S, Kuwabara Y, Ono K, Imai M, Inoue K, Murai T, Kita T, Kimura T, and Nishi E.　Nardilysin is a Promising Biomarker for the Early Diagnosis of Acute Coronary Syndrome. 　American Heart Association Scientific Sessions, 2016 Nov.12-16, New Orleans, LA, USA
  69. Keiji Uchiyama, Suehiro Sakaguchi. Sorting of prion protein and PrPSc accumulation. PRION 2016. Hitotsubashi Hall, National Center of Science Building, Tokyo May 10-13, 2016
  70. Matsumoto, G., Nukina, N, and Mori, N., Regulation of p62-mediated selective autophagy in brain,The 6th International Society of Radiation Neurobiology Conference, Ryojun Conference Center , Nagasaki University School of Medicine, Nagasaki, Japan, February 13th, 2016
  71. Matsumoto_G, Mori, N., p62-mediated selective clearance of damaged mitochondria in aged neurons, The 6th Busan-Nagasaki Joint Seminar on Aging Research, Seacloud Hotel Busan, Korea, March 11th, 2016
  72. 19th　International Symposium on Signal Transduction at the Blood-Brain-Barriers, Copenhagen, Denmark, 14-16 Sep, 2016
  73. Japan-Turkey International Symposium on Pharmaceutical and Biomedical Sciences, Kumamoto,Japan,2-3 Oct,2016
  74. Oka,M., Suzuki, E., Hisanaga, S., Iijima, KM, and Ando., K. “Reduction in ATP levels in the axon during aging and the role of mitochondrial distribution.” Society for Neuroscience’s the 46th annual meeting, San Diego, USA, November 2016
  75.  Ando, K., Maruko-Otake, A., Hayashishita, M., Oka, M., Ohtake, Y., Sekiya, M., Saito, T., Hisanaga, S., and Iijima, KM. Sustained activation of CaMKII caused by depletion of mitochondria from the axon enhances tau toxicity. 46th annual meeting of Society for Neuroscience, San Diego, USA, Nov 2016
  76. Hoshino K, Hayashi M, Isono Y, Nagao Y, Kimura K, Hachimori K, Nozaki H, Ohta E, Obata F, Kawarai T, Kaji K. Segawa disease with action retrocollis (cervical dystonia); A case report of 23-year-old female. 14th International Child Neurology Congress, Netherland (Amsterdam), 2016.5.4-5
  77. Yoshiaki Furukawa“A chaperone-independent maturation mechanism of Cu/Zn-superoxide dismutase”5th Symposium on Advanced Biological Inorganic Chemistry, Kolkata, India, January 7 – 11, 2017
  78.  Eiichi Tokuda, Itsuki Anzai, Takao Nomura, Shinji Ohara, Seiji Watanabe,Koji Yamanaka, Yuta Morisaki, Hidemi Misawa, and Yoshiaki Furukawa
     “In vivo and in vitro characterization of SOD1 in early stages of ALS as a precursor to insoluble aggregates” 27th International Symposium on ALS/MND, Dublin, Ireland, December 7-9, 2016
  79.  Itsuki Anzai, Eiichi Tokuda, Atsushi Mukaiyama, Shuji Akiyama, and Yoshiaki Furukawa “A folding intermediate of Cu/Zn-superoxide dismutase is susceptible to abnormal oligomerization implicated in amyotrophic lateral sclerosis” 8th Asian Biological Inorganic Chemistry Conference, Auckland, New Zealand, December 4 – 9, 2016
  80. Yoshiaki Furukawa, Teppei Kokubo, and Yasuyuki Sakurai “A dual role of cysteine residues in the activation of Escherichia coli Cu/Zn-superoxide dismutase” 8th Asian Biological Inorganic Chemistry Conference, Auckland, New Zealand, December 4 – 9, 2016
  81. Mami Fukuoka and Yoshiaki Furukawa “A mechanism on the allosteric activation of Cu/Zn-superoxide dismutase” 8th Asian Biological Inorganic Chemistry Conference, Auckland, New Zealand, December 4-9, 2016
  82. Yo-ichi Takei, Kenya Oguchi, Takaaki Miyahira, Akiyo Hineo, Akinori Nakamura, Shinji Ohara, and Yoshiaki Furukawa“Clinical and neuropathological study of an autopsied case of familial ALS with SOD1 mutation with very long survival” The 68th Annual Meeting of the American Academy of Neurology, Vancouver, Canada, April 15-21, 2016
  83. Masaki Fukata. (2016. 7.5) Postsynaptic nanodomains regulated by local palmitoylation machinery. 10th Forum of Neuroscience (FENS), (Copenhagen, Denmark)
  84. Masaki Fukata. (2016. 7.8) Molecular mechanisms of PSD95 (de)palmitoylation. Medizinische Hochschule Hannover, (Hannover, Germany)
  85. Masaki Fukata. (2016. 7.11) Postsynaptic nanodomains regulated by local palmitoylation machinery. Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) (Magdeburg, Germany)
  86. Masaki Fukata. (2016. 9. 9) The LGI1-ADAM22 protein complex in synaptic transmission and disorders. Brain protein aging and dementia control:　International workshop 2016, (Nagoya, Japan)
  87. Masaki Fukata. (2016. 10. 26) Regulatory mechanisms for AMPA receptors through PSD-95. The 47th NIPS International Symposium “Decoding Synapses” (岡崎)
  88. Shimizu S：”Identification of natural product against fatty liver disease based on the induction of alternative autophagy” ICNIM2016 (July 15-17, 2016, Sapporo, Japan)
  89. Shimizu S：”Alternative Autophagy is Essential for Neuronal Cell Maintenance” Brain Protein Aging and Dementia Control International Workshop (Sep 9, 2016, Nagoya)
  90. Shimizu S: “Mitophagy and alternative autophagy” The 13th Conference of Asian Society for Mitochondrial Research and Medicine (Oct 31, 2016, Shinagawa)
  91. 20TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS (MDS2016) JUNE 19-23 2016 BERLIN, GERMANY
  92. PRION 2016 TOKYO MAY 10-13 2016
  93. ANA2016, the American Neurological Association’s 141st Annual Meeting SAN DIEGO OCTOBER 15-17 2016
  94. 1ST INTERNATIONAL CONFERENCE OF KOREAN MOVEMENT DISORDER SOCIETY OCTOBER 28-30 2016
  95. College of Nutrition, Taipei Medical University Open House Symposium Jan 6th, 2017
  96. The American Society for Experimental Neurotherapeutics (ASENT) 19th Annual Meeting MARCH 15-17 2017 Rockville, Maryland
  97. Shinkai H., Niwa S., Kurimoto S., Okada Y., Hirata H. Reconstruction of Denervated Muscles Using Motor Neurons Derived from Mouse ES Cells 2017 annual meeting – Orthopaedic Research Society 2017.3
  98. Takashima A.:Mechanism of Neurodegeneration through Tau and Therapy for AD.(Keynote speaker)The 7th International High Level Forum on Exercise and Health – International Conference of Exercise Intervention on Alzheimer’s disease (ICEIAD),2016,5.7-8 , Shanghai, China
  99. 18. Hideyuki Okano : Challenge toward Spinal Cord Injury using iPS cell Technologies.: CiRA/ISSCR 2016 International Symposia,(Kyoto University Clock Tower Centennial Hall) 2016.3.24 Kyoto, Japan
  100. Matsumoto, G. Nukina, N. Mori, N.: p62-mediated selective autophagy in aged neurons, The 6th Busan-Nagasaki Joint Seminar on Aging Research, Seacloud Hotel in Busan,2016,3.11 South Korea　
  101. Furukawa Y:Protein conformational disorder leading to neurodegenerative diseases. The 3rd Mini-Symposium on Cutting-Edge Chemistry,2016,3.11 Hsinchu, Taiwan
  102. Takashima A.:Mechanism of Neurodegeneration through Tau and Therapy for AD.(symposium) The 1st International Gachon Neuroscience Symposium,2016,2. 24.Incheon, Korea.
  103. Okano H : Challenge toward Spinal Cord Injury and using iPS cell Technologies UK-JAPAN Life Innovation Symposium. : UK-JAPAN Life Innovation Symposium, (Tokyo Branch Kyoto University & LiSE KING SKYFRONT)2016.2.22 Sinagawa & Kawasaki, Japan

⬛︎2015

  1. Okano H : Modeling Human Neurological/Psychiatric Diseases using iPS cells and Transgenic Non-Human Primates. : Regenerative Medicine Seminar Series@Stanford,(Stanford University, Stanford) 2015.12.10 CA, USA
  2. Fukata M : Postsynaptic nanodomain regulated by PSD-95 palmitoylation machinery. Pacifichem 2015, 2015.12.15 Honolulu, HI, USA
  3. Okamura N:Busan Paik Hospital Neurodegenerative Disease Symposium, 2015, 11. 27, Busan
  4. Okano H : Modeling Psychiatric/Neurological disorders using iPS cell technologies and transgenic non-human primates. : THE 12TH NIKKO INTERNATIONAL SYMPOSIUM 2015 FRONTIERS IN TRANSLATIONAL NEUROSCIENCE,(JMU Education & Research Center) 2015.11.20 Shimotsuke, Japan
  5. Okano H : Transgenic and Genome Editing Technologies in Non-Human Primates. : TGE2015 Conference on Transposition and Genome Engineering 2015, Invited Lecture,(Nara Kasugano International Forum IRAKA)2015.11.19 Nara, Japan
  6. Mochizuki H :Parkinson’s disease and α-synuclein. Australian National University (ANU) & IPR Joint Symposium 2015 “PROTEIN STRUCTURE AND FUNCTION”.2015,11.16. Australia.
  7. Okano H : Preemptive Approaches for Neurodegenerative Disease and Dementia :　2015 WAFSF “Regenerative Medicine: Let’s Talk Business!”(Golden Gate Club)2015.11.12 San Francisco, USA
  8. Okano H : Modeling Psychiatric/Neurological disorders using iPS cell technologies and transgenic non-human primates.: 29th Annual Conference of he International Mammalian Genome Society, Keynote Lecture, (Yokohama Port Opening Memorial Hall) 2015.11.11. Yokohama, Japan
  9. Okano H : Modeling psychiatric/neurological disorders using ips cell technologies and transgenic non-human primates. : Cell Symposia:Human Genomics, (the Matrix building, 30 Biopolis Street)2015.11.9.Singapore
  10. Shimizu S “Biological Roles of Autophagic Cell Death”Japan Australia Meeting on Cell Death.2015,10.21-23 Melbourne
  11. Okamura N:2015 IPA 17th International Congress , 2015,10. 15, Berlin
  12. Yamaguchi Y: RIKEN-ACADEMIA Sinica Joint Conference on Chemical Biology, Taipei,2015,10.14-17 Taiwan
  13. Okano H : Modeling Neurological Diseases using iPS cells and Transgenic Non-human Primates. : The first International Symposium of Brain Protein Aging and Dementia Control, (Noyori Conference Hall),2015.10.10.Nagoya, Japan
  14. Hasegawa M: Molecular analyses of pathological tau in tauopathy brains. Brain Protein Aging and Dementia Control. 1st International Symposium. Molecular bases of brain protein aging. 2015. 10.9, Nagoya
  15. Onodera O:How does the cerebral small vessel system contribute the brain function in aging?–Lesson from the hereditary small vessel disease–Brain Protein Aging and Dementia Control 1st International Symposium　2015.10.9 Nagoya
  16. Okano H, Matsuo H, Nishimura Y, Hozumi K,Yoshioka S,Tonoki A, Itoh M, Ubiquitination of Dynamin 2 and Snx18 by Mib1 promotes Dll1 endocytosis and Notch signaling.
    Notch meeting, 2015,10.7 Athens,Greece
  17. Okano H : Preemptive Medicine for Dementia: Solutions for a ‘super-aging’ society. : International Conference on Cognitive Decline and Its Economic Consequences　国際会議「認知症社会における経済的挑戦と機会」, (North uilding Hall on Mita Campus, Keio University)
    2015.10.5 Tokyo, Japan
  18. Okano H : Regenerative Medicine and Disease Modeling with iPS cells technologies. :1th Annual Meeting of Korean Society for Stem Cell Research”Presidential Session -Today’s　Stem Cell　Research in Asia,(Grand Hilton Seoul Hotel) 2015.8.28,Seoul, Korea
  19. Okano H : Modeling Human Neurological Diseases using iPS cells and Transgenic Non-Human Primates : CHA Bio Complex Seminar, (CHA Bio Complex)2015.8.27 Seoul, Korea
  20. Hisanaga S, Kimura T: Reevaluation of physiological and pathological phosphorylation of tau in vitro to human brains 25th International Society for Neurochemistry,2015.8.23-25. Cairns, Australia,
  21. Okano H : Modeling Human Neurological/Psychiatric Disorders using iPS cells and Transgenic Non-Human Primates. : Breakthroughs in Molecular Genetics in Model Organisms Symposium,(UC Santa Barbara)2015.8.22 Santa Barbara, CA, USA
  22. Fukata M:Regulatory mechanism for local palmitoylation cycles on PSD-95.　FASEB Science Research Conference “Protein Lipidation, Signaling, and Membrane Domains 2015.7.22 Saxtons River, VT, USA)
  23. Okano H: Neuronal damage and regenerative medicine. : Center for Animal Disease Model International Symposium (CADMIS) 2015—Frontiers of Immunology and Neurobiology—(東京理科大学ヒト疾患モデル研究センター国際シンポジウム), 2015.7.21 Tokyo
  24. Furukawa Y:Lights and shadows of Cu,Zn-superoxide dismutase. The 17th International Conference on Biological Inorganic Chemistry,2015,7.20-24 Beijing, China
  25. Sobue G:Novel Imaging biomarker for early detection AD.International Symposium on Alzheimer’s Disease Prevention Strategy in Search of the Road to New Hrizon.
    2015.6.27 Tokyo
  26. Okano H : Modeling neurological and psychiatric disorders using iPSCs technologies and transgenic non-human primates. : The ISSCR Annual Meeting,(Stockholmsmassan Exhibition and Convention Center)2015.6.25 Stockholm, Sweden
  27. Okano　H : Brain Mapping Project in Japan:Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/ MINDS). : Cold Spring Harbor Asia (CSHA) Conference on International Brain Project,(Suzhou Industrial Park Conference Center, Suzhou, People’s Republic of China, PRC)2015.6.19　Suzhou、China
  28. Okano H : Disease Modeling and Brain Mapping using transgenic marmosets. : Janelia Marmoset Workshop ”The common marmoset as a transgenic model of the human brain in health and disease”,(Janelia Research Campus, Howard Hughes Medical Institute)2015.6.16 Virginia, USA
  29. Murakami T: Alteration of corticobulbar excitability during speech perception. International TMS Symposium 2015.6.7, Fukushima
  30. Okamura N: SNMMI 2015 Annual Meeting, 2015,6.6,Baltimore
  31. 4. Hideyuki Okano : Using Genetics to Deconstruct Neural Circuits session　Alpbach Congress Centrum in Alpbach（2016 Keystone Symposia on The Brain, Austria)2015.05.23-27 Alpbach,Austria
  32. Yamaguchi Y :RIKEN-Max Planck Joint Research Center for Systems Chemical Biology 3rd Annual Symposium,2014,5.21-24 Kreuth, Germany
  33. Okano H : Brain Mapping and Modeling Human Psychiatric/Neurological Disorders using Transgenic technologies and Genome-Editing in Non-human Primates.（Scientific meeting on animal models of neurodegenerative Disorders) 2015.05.02.Paris, France）
  34. Okano H : Brain Science and Modeling Neurological Diseases using Transgenic and Genome Editing Technologies. : Dr. Austin Smith Lab Seminar,(Stem Cell Institute, University of Cambridge),2015.4.22 Cambridge, UK
  35. Okano H : Modeling Human Psychiatric/Neurological Disorders using Transgenic technologies and Genome-Editing in Non-human Primates. (24 th annual Colloque Médecine et Recherche in the Neurosciences series,FranceGenome Editingin Neurosciences) #Cloud ,2015.04.21.Paris
  36. Okano H : Modeling Psychiatric/Neurological disorders using iPS cell technologies and transgenic non-human primates.International Symposium on Cell Physiology and Aging Research　 Kaohsiung Medical University (KMU),2015,4.12 Kaohsiung, Taiwan
  37. Hisanaga, S:Neuronal protein kinase LMTK1 regulates neurite outgrowth through Rab11-dependent endosomal trafficking in a Cdk5-dependent manner EMBO Workshop,
    2015.3.23-26,PUERTO MONTT, Chile,
  38. Okamura N: ADPD Imaging Symposium 2015, 2015,3. 17, Nice
  39. Takashima A: Aging and Tau (symposium)Asian Aging Core for Longevity (AACL) 10 years and Beyond Japan-Korea Joint Seminars, Osaka, Japan. 2015,3.12, 2015
  40. Okano H：Brain Science using Transgenic non-Human Primates：第５回新潟大学脳研究所共同研究拠点国際シンポジウム BRI International Symposium 2015 Genome Editing Technology; its Current State-of-Art and Application to Brain Research, Keynote lecture, (Center for Integrated Human Brain Science (6F), Niigata University)2015.3.6 Niigata
  41. Okano H : Cell transplantation therapies for spinal cord injury focusing on human iPS cells.The 18th Takeda Science Foundation Symposium on Bioscience”iPS Cells for Regenerative Medicine”, (Center for Learning and Innovation (CLI), Takeda Pharmaceutical Company, Ltd.) 2015.1.15 Suita

⬛︎2014

  1. Suhara T, Nagai Y, Yukiko H, Ji B, Higuchi M, Minamimoto T: In vivo imaging of designer receptor that enables to modify cell function and reward-related behavior in monkeys, NSFC-CAS-JSPS International Workshop on Frontier of Science and Technology 2014, 2014.12.06, China
  2. Okano H: Modeling psychiatric/neurological disorders using iPS cell technologies and transgenic non-human primates. : BROAD Institute Seminar, Auditorium, BROAD Institute,2014.12.4 MA, USA
  3. Sahara N,Ono M, Koga S, Maeda J,Matsumoto I, Dennis W. Dickson, Zbigniew K. Wszolek, Ming-Rong Zhang, Suhara T, Higuchi M:Visualization of tau lesions in brains of tauopathy patients and model mice using tau ligand PBB3 2014北米神経科学学会, 北米神経科学会, 2014-11-17(本発表はSFN2014, Hot Topicsに選出） Washington, DC,USA
  4. Fujioka Y,Ishigaki S,Shiromizu T, Udagawa T, Yokoi S, Honda D, Ikenaka K,Katsuno M,Tomonaga T and Sobue G: The involvement of glial cells in FUS-related ALS/FTLD pathophysiology –FUS knock-down glial cells have a neuro-protective effect.The 43rd Society for Neuroscience annual meeting,2014.11.15-19 Washington DC,
  5. Okano H : Transgenic marmosets for modeling human nuerological and psychiatric disorders: Minisymposium 668 “Transgenic Primate Models of Human Brain” at Neuroscience 2014,(the Walter E. Washington Convention Center)2014.11.19 Washington DC, USA
  6. Okano H : Transgenic marmosets for modeling human nuerological and psychiatric disorders: Minisymposium 668 “Transgenic Primate Models of Human Brain” at Neuroscience 2014(the Walter E. Washington Convention Center)2014.11.19 Washington DC, USA
  7. Okano H : Brain Mapping Project in Japan:Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/ MINDS). : the Public Advocacy Forum at Neuroscience 2014,(the Walter E. Washington Convention Center)2014.11.18 Washington DC, USA
  8. Okano H : Brain Mapping by Integrated Neurotechnologies for disease Studies. : Marmoset Social,(Renaissance Washington, DC Downtown Hotel) 2014.11.17 Washington DC, USA
  9. Hideyuki Okano : iPS Cell Technologies:Significance and Applications to CNS Regeneration and Disease Research. :2014 WASF on Stem Cell Research and Regenerative Medicine “The Impact of Regenerative Medicine 2014”,Mission Bay Converence Center at UCSF,2014.11.6 San Francisco, USA
  10. Hasegawa M: Prion-like properties of pathological proteins from diseased brains. Brain Conference 2014, Symposium 4「Pathological propagation in neurodegenerative diseases」2014.11.6 Seoul, Korea
  11. Okano H: iPS Cell Technologies:Significance and Applications to CNS Regeneration and Disease Research. :2014 WASF on Stem Cell Research and Regenerative Medicine “The Impact of Regenerative Medicine 2014”(Mission Bay Converence Center at UCSF) 2014.11.6 San Francisco, USA
  12. Okano H : Application of human iPS cells for inner ear biology and human disease modelin. :Inner Ear Biology Workshop 2014 in Kyoto, Lecture, (Kyoto International Conference Center)2014.11.3 Kyoto, Japan
  13. Okamura N:Tau and Amyloid Imaging. Outlook for the Future. EANM 2014,2014.10.21, 　Gothenburg, Sweden
  14. Okamura N, Furumoto S, Harada R, Tago T, Iwata R, Tashiro M, Furukawa K, Arai H, Yanai K, Kudo Y:Characterization of [18F]THK-5351, a novel PET tracer for imaging tau pathology in Alzheimer’s disease. EANM 2014, 2014.10.21 Gothenburg, Sweden
  15. Okamura N:Tau-Imaging. Results of First-in Human Studies. EANM 2014 Pre-Congress Symposium 6: TAU and Amyloid: From Neuropathology to Neuroimaging,2014.10.18 Gothenburg, Sweden
  16. Okano H: Modeling neurological and psychiatric disorders using iPSC technologies and transgenic non-human primates. : BRIDGING BIOMEDICAL WORLDS (BBW 2014) – Turning obstacles into opportunities for stem cell therapy, (China National Convention Center),
    2014.10.14 Beijing, PR China
  17. Sugai A,Kato T, Koyama A, Nishizawa M, Onodera O: Endogenous TDP-43 over-expression model with disrupted auto-regulation : 10th Annual Meeting of the Oligonucleotide Therapeutics Society.Hilton San Diego Resort & Spa,2014,10.12-15 San Diego, California
  18. Okamura N:Imaging neurofibrillary pathology in Alzheimer’s disease using novel tau PET tracer. 14th ICGP & 19th JSNP Joint Congress, 2014.10.3 Tsukuba, Japan
  19. Okano H : The Brain Mapping Project in Japan: Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/ MINDS). : Human Brain Project (HBP) Summit　2014, Kirchhoff Institute for Physics（KIP),2014.9.29 Heidelberg, Germany
  20. Sahara N : Tau PET imaging: New insight into early diagnosis of tauopathy 2nd International Conference on Alzheimer”s Disease & Dementian,
    OMICS Publishing Group, 2014-09-23
  21. Takashima A: Tau /tau interaction through Cys residue form a toxic tau aggregate.(symposium)7th Asian Aging Core for Longevity (AACL) conference in Jeju,2014,9.22 Jeju, Korea.
  22. Hasegawa M: Prion-like features in alpha-synucleinopathies. XVIIIth International Congress of Neuropathology 2014. W3: Prion-like mechanisms in neurodegenerative disorders.2014.9.15 Rio de Janeiro, Brazil
  23. Osamu O, Masatoyo N, Hitoshi T: Update in amyotrophic lateral sclerosis: he XVIII International Congress of Neuropathology. ICN 2014, Rio de Janeiro, Brazil, 2014.9.14-18
  24. Hasegawa M: Pathological alpha-synuclein spreading explains the disease progression. Neuroscience 2014. Joint Symposium of the Japan Neuroscience Society and the Korean Society of Brain and Neuroscience: Molecular Mechanisms underlying Parkinson Disease.2014,9.12 Yokohama,Japan
  25. Okano D : Modeling neurological and psychiatric disorders using iPSC technologies and transgenic non-human primates. BRIDGING BIOMEDICAL WORLDS (BBW 2014) – Turning obstacles into opportunities for stem cell therapy,China National Convention Center (CNCC),2014.10.14 Beijing, PR China
  26. Sahara N:Tau imaging.the frontier of neuroimaging in neurodegenerative disease
    Autonomous University of Madrid セミナー, 2014-09-26 Madrid,Spain
  27. 2. Suhara T:In vivo Tau PET Imaging Using[11C]PBB3 in Alzheimer’s Disease and Non-Alzheimer’s Disease Tauopathies, 2014 Taiwan International Symposium of Molecular Imaging and 2014 Annual Meeting of Taiwanese Society for Molecular Imaging, 2014.09.12, Taipei
  28. Ishigaki S, Fujioka Y, Udagawa T, Honda D, Yokoi S, Katsuno M, Okado H, and Sobue G:Quality loss of FUS and SFPQ in the nucleus causes FTLD-like behavioral abnormalities by modulating Tau isoforms. The 37th annual Meeting of the Japan Neuroscience Society　2014.9.11-13 Yokohama, Japan
  29. Fujioka Y,Ishigaki S,Shiromizu T, Udagawa T, Yokoi S, Honda D, Ikenaka K, Katsuno M, Tomonaga T, and Sobue G:The involvement of glial cells in FUS-related ALS/FTLD pathology-FUS knock-down glial cells have a neurotrophic effect.The 37th annual Meeting of the Japan Neuroscience Society　2014.9.11-13 Yokohama, Japan
  30. Koyama A, Sugai A, Kato T, Konno T,Ishihara T, Nishizawa M, Onodera O: TDP-43 is autoregulated by multiple excisions of introns in exon6 and reservation of mRNA in nucleus by TDP-43. The 37th Annual Meeting of the Japan Neuroscience Society. 2014,9.11-13 Yokohama
  31. Shiga A, Kondo C, Hirokawa S, Tsukie T, Miyashita A, Nishizawa M, Onodera O: Alternation of miRNA expression in TDP-43 depleted spinal motor neuron. The 37th Annual Meeting of the Japan Neuroscience Society. 2014,9.11-13 Yokohama
  32. Kato T,Koyama A, Sugai A, Toyoshima Y, Takahashi H, Nishizawa M, Onodera O: Analysis of intracellular distribution of TDP-43 mRNA in affected spinal motor neuron with ALS. The 37th Annual Meeting of the Japan Neuroscience Society.2014,9.11-13 Yokohama
  33. Onodera O: RNA metabolism and ALS. The 37th Annual Meeting of the Japan Neuroscience Society.2014,9.11-13 Yokohama
  34. Hisanaga, S., Kimura, T:Reevaluation of physiological and pathological phosphorylation of tau in vitro to human brains 25th ISN meeting,2015,8. 23-25 Cairns, Australia,
  35. Takahashi M, Nonaka T, Kametani F, Hisanaga S, Hasegawa M:Treatment of cells expressing APP with tau fibrils induces intracellular aggregate formation of tau. Alzheimer’s Association International Conference (AAIC2014); 2014. 7. 16. Copenhagen, Denmark
  36. Nonaka T, Masai H, Hasegawa M:Phosphorylation of TDP-43 by casein kinase 1 delta facilitates mislocalization and intracellular aggregate formation of TDP-43. Alzheimer’s Association International Conference (AAIC2014); 2014. 7. 15. Copenhagen, Denmark
  37. Ono M, 季　斌, Sahara N, Tokunaga M, Komatsu M,Tanaka K,Ichikawa M,Warabi E, Suhara T, Higuchi H:Pivotal roles of p62 and selective autophagy in neurodegeneration revealed with tauopathy mouse models Alzheimer’s Association International Conference, 2014 Alzheimer’s Association, 2014-07-15 Toronto, Canada
  38. Sahara N,Wen-Lang Lin, Perez Pablo,Higuchi H,Suhara T, Marcelo Febo :Age-related white matter pathogenesis in a mouse model of Tauopathy Alzheimer’s Association International Conference 2014, Alzheimer’s Association,2014,7.15 Toronto, Canada
  39. Takashima A: Granular tau oligomer as toxic tau aggregation form in AD.
    Alzheimer’s Association International Conference 2014, Copenhagen, Denmark. 2014,7.14,
  40. Sahara N, Wen-Lang Lin, Perez Pablo, Higuchi M, Suhara T, Marcelo Febo:Age-related white matter pathogenesis in a mouse model of Tauopathy Alzheimer’s Association International Conference 2014, Alzheimer’s Association,2014-07-13　Toronto, Canada
  41. Okamura N, Harada R, Furumoto S, Furukawa K, Ishiki A,Tomita N, Tashiro M, Iwata R, Yanai K, Arai H, Kudo Y:Comparison of 18F-THK5117 and 11C-PiB PET images in the patients with Alzheimer’s disease. AAIC 2014, 2014.7.12-17,Copenhagen
  42. Harada R, Okamura N, Furumoto S, Tago T, Yoshikawa T,Akatsu H, Arai H, Iwata R, Yanai K, Kudo Y:Binding characterization of tau PET tracer 18F-THK5117 in non-Alzheimer’s neurodegenerative diseases. AAIC 2014,2014.7.12-17, Copenhagen
  43. Okano　H : Brain science using iPS Cell technology and transgenic non-human primates. 29th CINP World Congress of Neuropsychopharmacology (CINP-The International College of Neuropsychopharmacology), Plenary Lecture, Vancouver Centre,2014.6.24 Vancouver, Canada
  44. Hasegawa M: Prion-like propagation of pathological proteins in neurodegenerative diseases. 2014 Yonsei BK21 PLUS – Igakuken Joint Symposium,2014, 6. 19.Seoul, Korea
  45. Okamura N, Furumoto S, Harada R, Furukawa K, Ishiki A, Iwata R, Tashiro M, Yanai K, Arai H, Kudo Y: In vivo selective imaging of tau pathology in　Alzheimer’s disease with 18F-THK5117. SNMMI 2014 Annual Meeting, 2014.6. 9, St. Louis
  46. Okamura N: Advances in Tau PET. SNMMI 2014 Annual Meeting, 2014.6. 8, St. Louis